Danilo D'Avino

Mr. Danilo D'Avino

Department of Pharmacy, University Federico II, Naples, Campania, Italy
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Danilo D'AvinoDanilo D'Avino
Danilo D'Avino
ICIda Cerqua
Ida Cerqua
HUHammad Ullah
Hammad Ullah
MSMichele Spinelli
Michele Spinelli
RMRita Di Matteo
Rita Di Matteo
Antonietta RossiAntonietta Rossi
Antonietta Rossi
Astragalus membranaceus (Fisch.) Bunge root is used as herbal medicine for its immunomodulating activities in Chinese medicine. Recently, beneficial properties of A. membranaceus on allergic diseases have been proposed. Here we investigated the role of a commercial extract of A. membranaceus, standardized to 16% polysaccharides, in regulating the immune-inflammatory response in vitro and in vivo and its therapeutic application in asthma. A. membranaceus extract inhibited prostaglandin E2 and leukotriene C4 production in stimulated J774 and peritoneal macrophages, respectively. The extract also reduced interlukin-1β, tumor necrosis factor-α, and nitrite production, affecting inducible nitric oxide synthase expression. In vivo experiments confirmed the anti-inflammatory properties of A. membranaceus, as evident by a reduction in zymosan-induced peritoneal cellular infiltration and pro-inflammatory mediator production. The efficacy of A. membranaceus extract in modulating the immune response was confirmed in a model of allergic airway inflammation. Extracts improve lung function by inhibiting airway hyperresponsiveness, airway remodeling, and fibrosis. Its anti-asthmatic effects were further sustained by inhibition of the sensitization process, as indicated by a reduction of ovalbumin-induced IgE levels and the mounting of a Th2 immune response. In conclusion, our data demonstrate the anti-inflammatory properties of the commercial extract of A. membranaceus and its beneficial effects on asthma feature development.

1 November 2022 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
ICIda Cerqua
Ida Cerqua
SMSimona Musella
Simona Musella
LPLukas Klaus Peltner
Lukas Klaus Peltner
Danilo D'AvinoDanilo D'Avino
Danilo D'Avino
VSVeronica Di Sarno
Veronica Di Sarno
Alessia BertaminoAlessia Bertamino
Alessia Bertamino
The design of multitarget drugs represents a promising strategy in medicinal chemistry and seems particularly suitable for the discovery of anti-inflammatory drugs. Here, we describe the identification of an indoline-based compound inhibiting both 5-lipoxygenase (5-LOX) and soluble epoxide hydrolase (sEH). In silico analysis of an in-house library identified nine compounds as potential 5-LOX inhibitors. Enzymatic and cellular assays revealed the indoline derivative 43 as a notable 5-LOX inhibitor, guiding the design of new analogues. These compounds underwent extensive in vitro investigation revealing dual 5-LOX/sEH inhibitors, with 73 showing the most promising activity (IC50s of 0.41 ± 0.01 and 0.43 ± 0.10 μM for 5-LOX and sEH, respectively). When challenged in vivo in zymosan-induced peritonitis and experimental asthma in mice, compound 73 showed remarkable anti-inflammatory efficacy. These results pave the way for the rational design of 5-LOX/sEH dual inhibitors and for further investigation of their potential use as anti-inflammatory agents.

19 June 2023 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
SMSimona Musella
Simona Musella
Danilo D'AvinoDanilo D'Avino
Danilo D'Avino
LPLukas Klaus Peltner
Lukas Klaus Peltner
VSVeronica Di Sarno
Veronica Di Sarno
ICIda Cerqua
Ida Cerqua
Alessia BertaminoAlessia Bertamino
Alessia Bertamino
Acute pancreatitis (AP) is a potentially life-threatening illness characterized by an exacerbated inflammatory response with limited options for pharmacological treatment. Here, we describe the rational development of a library of soluble epoxide hydrolase (sEH) inhibitors for the treatment of AP. Synthesized compounds were screened in vitro for their sEH inhibitory potency and selectivity, and the results were rationalized by means of molecular modeling studies. The most potent compounds were studied in vitro for their pharmacokinetic profile, where compound 28 emerged as a promising lead. In fact, compound 28 demonstrated a remarkable in vivo efficacy in reducing the inflammatory damage in cerulein-induced AP in mice. Targeted metabololipidomic analysis further substantiated sEH inhibition as a molecular mechanism of the compound underlying anti-AP activity in vivo. Finally, pharmacokinetic assessment demonstrated a suitable profile of 28 in vivo. Collectively, compound 28 displays strong effectiveness as sEH inhibitor with potential for pharmacological AP treatment.

22 July 2024 in The FASEB Journal
Verified
Journal Article
Open access
SPSimona Pace
Simona Pace
KMKatharina Paula Lydia Meyer
Katharina Paula Lydia Meyer
FTFabiana Troisi
Fabiana Troisi
RBRossella Bilancia
Rossella Bilancia
Danilo D'AvinoDanilo D'Avino
Danilo D'Avino
OWOliver Werz
Oliver Werz
Unresolved inflammation, due to unfavorable imbalances between pro‐inflammatory and pro‐resolving mediators, leads to chronic inflammatory pathologies that are often sex‐biased and regulated by sex hormones, including inflammatory bowel disease. Lipid mediators (LM) produced from polyunsaturated fatty acids by various lipoxygenases (LOX) and cyclooxygenases govern all stages of inflammation, i.e., the initiation and progression by pro‐inflammatory eicosanoids and its resolution by specialized pro‐resolving mediators (SPM). Here, we reveal sex‐specific differences in murine experimental colitis with male preponderance, which was abolished by sex hormone deprivation using gonadectomy, and this correlated to the levels of inflammation‐relevant mediators in the colon. Oral dextran sodium sulfate administration caused more severe colon inflammation in male CD‐1 mice than in female counterparts during the acute phase. Colitis in males yielded higher colonic cytokine/chemokine levels but lower 12−/15‐LOX‐derived LM including SPM compared to female animals in the resolving phase. Sex hormone deprivation in male mice by orchidectomy ameliorated colitis and impaired pro‐inflammatory cytokine/chemokine levels but elevated 12−/15‐LOX products including SPM, thus abolishing the observed sex differences. Conversely, ovariectomy impaired the levels of those LM that dominated in females and that were increased in males after gonadectomy. Our findings suggest that male sex hormones promote the development of colitis connected to the biosynthesis of inflammatory cytokines, chemokines, and certain LM, especially pro‐resolving 12−/15‐LOX products that appear to be suppressed in the male colon due to androgens.

14 January 2026 in British Journal of Pharmacology
Verified
Journal Article
Closed access
Danilo D'AvinoDanilo D'Avino
Danilo D'Avino
ICIda Cerqua
Ida Cerqua
L. MaruccioL. Maruccio
L. Maruccio
KMKatharina P. L. Meyer
Katharina P. L. Meyer
CQCristina Quintavalle
Cristina Quintavalle
Antonietta RossiAntonietta Rossi
Antonietta Rossi

28 May 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
LWLorenz Waltl
Lorenz Waltl
KSKlaus Speck
Klaus Speck
RWRaphael Wildermuth
Raphael Wildermuth
FHFranz-Lucas Haut
Franz-Lucas Haut
SPStephan Permann
Stephan Permann
Andreas KoeberleAndreas Koeberle
Andreas Koeberle
Lipidomics-guided screening of unexplored chemical space in natural products provides access to small molecules capable of modifying cellular lipid profiles on a global scale. Here, we show that the meroterpenoid cyclosmenospongine from Spongia sp . shapes the lipid profile of immune cells, favoring anti-inflammatory and pro-resolving over pro-inflammatory lipid mediators. Structural variation revealed derivatives that inhibit leukotriene biosynthesis to varying extents while differentially upregulating pro-resolving lipid mediators, epoxyeicosatrienoic acids, endocannabinoids, and sphingosine-1-phosphate, along with other mediators, both in resting and activated innate immune cells in vitro and in self-resolving murine peritonitis in vivo . Mechanistically, meroterpenoids target 5-lipoxygenase or 5-lipoxygenase-activating protein, promote the translocation of 15-lipoxygenase-1 to cytoplasmatic sites, and inhibit monoacylglycerol lipase. They also redirect arachidonic acid (AA) from neutral lipids to specific phospholipids, while increasing the total concentration of free AA. Furthermore, meroterpenoids reprogram lipid metabolism in immune cells, decreasing the levels of neutral lipids, triacylglycerols, and cholesteryl esters. This shift correlates with a reduced capacity for leukotriene biosynthesis and is mimicked by the inhibition of sterol-O-acyltransferase and diacylglycerol acyltransferase-1/2. In conclusion, specific meroterpenoids exert anti-inflammatory effects by intervening in lipid mediator biosynthesis, prompting structure-controlled switches in lipid mediator classes, among others, through an unexpected link between lipogenesis and inflammation.